Neurelis是devleops的专业制药公司和独占鳌头的产品适合癫痫和更广泛的中枢神经系统(CNS)市场。

Ikano疗法是一种专业制药公司专注于发展鼻地交付医药产品与特定关注药物治疗疼痛和疾病相关的中枢神经系统。

Indena是一家致力于识别、开发和生产的活动原则来源于植物,用于制药、保健食品和化妆品行业。Indena、民营意大利公司约有700名员工,其中包括10%致力于全职研究,旨在培养管理,制造、分销业务在全世界40多个国家。Indena成功的关键是它的研究,包括:药用植物的药理筛选的好处;识别新的活跃的原则;提取和纯化系统的开发和工业应用的前沿。phyto-chemical研究进行Indena Settala自己的研究中心,意大利。Indena同样也与世界上最著名的大学和私人研究机构在生物的安全性和有效性临床评估阶段i的主要战略目标之一的医药研究开发新的积极的原则的应用程序。这也是一个不可缺少的保健食品和化妆品行业的基础。在制药行业Indena目前专注于抗癌治疗的发展,紫杉醇的成功后,以及在抗菌和抗病毒药物。还在研究是活跃的原则治疗病态和中枢神经系统功能障碍,如抑郁,焦虑,阳痿,睡眠障碍、感觉过敏。 Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

公司从事药物开发和商业化的医院治疗中枢神经系统(CNS)疾病和血栓性心血管疾病、适应症,有大量的未满足的医疗需要。

NeuroMolecular药品开发和商业化比神经保护药物治疗中枢神经系统(CNS)疾病。神经精神产品的公司已经建立了一个健壮的管道根据科学家的独特理解谷氨酸核心作用的调节中枢神经系统紊乱。NeuroMolecular是其迅速发展的新一代药物进入临床研究,临床项目进行中抑郁、痛苦,阿尔茨海默氏症、帕金森病、多发性硬化症和癫痫。NeuroMolecular最初专注于优越的发展衍生品和美金刚胺剂量配方,一种药物最近批准的美国食品和药物管理局(FDA)治疗阿尔茨海默氏症。

Intarcia疗法是一种基于生物制药公司在波士顿,马萨诸塞州。Intarcia从事开发的管道产品的专有美第奇药物输送系统由三个技术:稳定技术,允许蛋白质、多肽、抗体片段,和其他高度有效的小分子是稳定在或高于人体温度,一个matchstick-sized渗透mini-pump放置在皮肤的真皮层提供药物,连续和一致的流动和放置技术包括专用工具旨在提供最优的用户体验。